Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Appendix 4C Quarterly Cash Flow Report 30 June 2013

31July 2013 – Sydney, Australia & Auckland, New Zealand –Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 30 June 2013. The Appendix 4C is attached. The company ended the quarter with a cash balance of A$4,504,000 compared to $4,906,000 last quarter.

Dr Andrea Grant, Managing Director, said "I am pleased to see that LCT's net cash flow continues to be well controlled, despite the company supporting two human clinical trial programs. This is because the costs associated with both clinical programs are being recouped, through the joint venture Diatranz Otsuka Limited for DIABECELL® as a treatment for type 1 diabetes; and through the co-development partnership with Otsuka Pharmaceutical Factory, for NTCELL® as a treatment for Parkinson's disease".

Net operating cash flow in the quarter was ($398,000) compared to $2,553,000last quarter. Receipts from customers were $2,178,000 (last quarter $4,808,000). The prime reason for the decrease in these items is the receipt in the last quarter of the $3,000,000 option fee,less a $150,000 withholding tax,from Otsuka Pharmaceutical Factory, Inc.

Operating payments were $2,640,000 compared to $2,289,000 last quarter. 83% of these payments are recovered as receipts from customers through LCT's co-development and joint venture agreements as they includecostsfor NTCELL clinical development and the services provided to Diatranz Otsuka Limited for the development of DIABECELL.

– Ends –

For further information: www.lctglobal.com

At the company:	**Media enquiries:**
Dr Andrea Grant Managing Director Tel: +64 9 270 7941 Mobile: +64 21 078 5421 agrant@lctglobal.com John Cowan Head of Finance & Administration Tel: +64 9 276 2690 Mobile: +64 21 469000 jcowan@lctglobal.com	Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need.To date, the company has taken two therapeutic candidates into clinical development: DIABECELL®, which is currently in late-stage clinical trials for the treatment of Type 1 diabetes and is on track to be commercially available in 2016; and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease.

Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECELL and the Phase I clinical trials of NTCELL in Parkinson's disease. LCT retains a 50% share of future profits from DIABECELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the joint venture.

LCT's unique, proprietary technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer